PRTG Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
|
